Adding cagrilintide beats semaglutide alone, but does nothing extra for blood sugar

Semaglutide 2.4 mg has become the reference drug for weight management, but plenty of people taking it never reach the ambitious weight-loss targets they or their clinicians had in mind. That has pushed drug development towards combinations that attack appetite and energy balance through more than one route at once. CagriSema is a fixed-dose pairing of cagrilintide with semaglutide, on the theory that complementary mechanisms deliver more than either alone. The practical question for anyone weighing up options is how much extra weight loss the combination actually buys, and what it costs in side effects.

The authors ran a registered review following PRISMA 2020 methods, searching PubMed, Embase, Cochrane CENTRAL, ScienceDirect, ClinicalTrials.gov and the WHO trials registry up to 30 June 2026. They looked for randomised controlled trials comparing CagriSema against either semaglutide 2.4 mg or placebo in adults with overweight or obesity, with and without type 2 diabetes. Five trials covering 4,746 unique participants met the criteria. Results were pooled in two prespecified comparison groups using random-effects models, with prediction intervals, leave-one-out checks, analyses restricted to phase 3a trials, and a trial sequential analysis to test whether enough data had accumulated.

Against semaglutide 2.4 mg, CagriSema produced greater weight loss by 6.89 percentage points, an absolute reduction of 7.16 kg, and a body-mass index drop of 2.41 kg/m². Participants were roughly twice as likely to reach a 20% reduction in body weight, and waist circumference fell a further 4.07 cm. Blood sugar told a different story: no incremental benefit was detected, with both glycated haemoglobin and fasting plasma glucose results falling entirely within the range considered too small to matter. Injection-site reactions were around three times more frequent, while gastrointestinal side effects were not significantly increased under the main analysis.

This consolidates what individual trials had hinted at, that layering cagrilintide onto semaglutide adds meaningful weight loss rather than a token amount. The surprise is the clean separation between weight and glycaemic outcomes: the combination moved the scale and the waistline without improving blood sugar markers beyond semaglutide's own effect. The authors are explicit about what remains unknown. The evidence is insufficient to say whether serious adverse events or new growths differ between the two treatments, and long-term durability, cardiovascular outcomes and body composition are all undetermined.

If you are following the obesity drug pipeline, this is a reason to think the next generation of combination injectables genuinely outperforms the current benchmark on weight, by a margin large enough to notice. It is also a reason to temper expectations about metabolic health more broadly, since better blood sugar did not come along for the ride here. The higher rate of injection-site reactions is a real trade-off worth factoring in. And because nobody yet knows how much of the lost weight is fat rather than lean tissue, the body composition question stays open.